Cingulate Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Cingulate Inc. (CING) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.26% for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2024-11-07
- Cingulate Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 3.66%, a 0.05% decline year-over-year.
- Cingulate Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 3.66%, a 137.79% increase year-over-year.
- Cingulate Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-03-31 was 1.54%.
- Cingulate Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.75%, a 98.46% increase from fiscal 2022.
- Cingulate Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 1.89%, a 15641.67% increase from fiscal 2021.
- Cingulate Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2021 was 0.01%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|---|
| 2024-09-30 | 4.26% 10-Q · filed 2024-11-07 | ||||
| 2024-06-30 | 4.32% 10-Q · filed 2024-08-13 | ||||
| 2024-03-31 | 3.66% 10-Q · filed 2024-08-13 | 3.98% 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | 3.75% 10-K · filed 2024-04-01 | ||||
| 2023-09-30 | 4.07% 10-Q · filed 2023-11-13 | ||||
| 2023-06-30 | 3.61% 10-Q · filed 2023-08-14 | ||||
| 2023-03-31 | 3.66% 10-Q · filed 2024-05-08 | ||||
| 2022-12-31 | 1.89% 10-K · filed 2024-04-01 | ||||
| 2022-09-30 | 1.71% 10-Q · filed 2022-11-14 | ||||
| 2022-03-31 | 1.54% 10-Q · filed 2023-05-10 | ||||
| 2021-12-31 | 0.01% 10-K · filed 2023-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |